Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Andrea Calcagno, Antonio D'Avolio, Stefano Bonora

Journal: Expert opinion on drug metabolism & toxicology 2016;11(7):1167-76

PMID: 26073580

Abstract

INTRODUCTION

Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

AREAS COVERED

This review covers material searched and obtained through Medline and PubMed up to April 2015.

EXPERT OPINION

Raltegravir for its tolerability, efficacy, few drug-to-drug interactions and for the amount of available data in difficult subgroups of patients is a key drug in the antiretroviral armamentarium. For its weak genetic barrier to resistance and erratic pharmacokinetic profile, it should be administered twice daily and with fully active companion antiretrovirals.

Address: University of Torino, Amedeo di Savoia Hospital, Unit of Infectious Diseases, Department of Medical Sciences , C.so Svizzera 164 - 10149, Torino , Italy + 39 011 439 3884 ; + 39 011 439 3942 ; [email protected].

DOI: 10.1517/17425255.2015.1056732

Link outs

Free resources

Medical:

https://medlineplus.gov/hiv.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-1595

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.1517/17425255.2...

MeSH Terms: Drug Interactions, Drug Resistance, Viral, HIV Infections, HIV Integrase Inhibitors, HIV-1, Humans, Raltegravir Potassium